Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study.
Fifty psoriatic patients enrolled in a three week, double-blind, randomized, parallel study were treated either with amcinonide ointment 0.1 percent twice a day or fluocinonide ointment 0.05 percent three times a day. After Week 1 of treatment, no statistically significant differences appeared between the two groups with regard to improvement in signs and symptoms of psoriasis. After Week 3, improvement in all efficacy parameters, except erythema, and in Total Scores in both groups was greater than 50 percent as compared to baseline evaluations. There were no statistically significant differences between the treatment groups. Only one patient in each group reported an adverse experience that could have been drug-related. Amcinonide ointment used twice a day and fluocinonide ointment used three times a day were judged comparable with regard to safety and clinical efficacy. Amcinonide may be considered to have some advantage over fluocinonide because its twice a day treatment schedule makes it more convenient for patients to use.
D000287:Administration, Topical; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005446:Fluocinolone Acetonide / Q000031:analogs & derivatives*; D005447:Fluocinonide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D011897:Random Allocation; D014221:Triamcinolone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D005446:Fluocinolone Acetonide; D014221:Triamcinolone; D005447:Fluocinonide; C012716:amcinonide